Literature DB >> 17557868

Epigenetic dysregulation of the death-associated protein kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in multiple myeloma.

Chor-Sang Chim1, Raymond Liang, Tsz-Kin Fung, Chi-Lung Choi, Yok-Lam Kwong.   

Abstract

AIM: To study the role of gene promoter hypermethylation of the putative tumour suppressor genes involved in the death-associated protein (DAP) kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in multiple myeloma (MM).
METHOD: DNAs from 55 primary MM marrow samples and myeloma cell lines were analysed for aberrant promoter methylation of DAP kinase, p14 and Apaf-1 genes by methylation-specific polymerase chain reaction (MSP). RESULT: In the methylated positive control, the sensitivity of M-MSP for DAP kinase was 1 x 10(-3). Aberrant hypermethylation of DAP kinase was found in 29/55 (52.7%) primary MM samples, whereas hypermethylation of p14 or Apaf-1 was undetectable in any of the samples tested. 5-Azacytidine treatment of two myeloma cell lines, WL2 and HS-Sultan, led to de-methylation and re-expression of DAP kinase, thereby confirming gene silencing associated with promoter hypermethylation. Hypermethylation of DAP kinase did not correlate with age, sex, paraprotein subtype or Durie-Salmon stage, but negatively affected the overall survival.
CONCLUSION: Of the putative tumour suppressor genes in the DAP kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway, only DAP kinase is frequently methylated in MM, which is associated with gene silencing and might be of prognostic significance. p14 and Apaf-1 were not methylated in MM.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17557868      PMCID: PMC1955062          DOI: 10.1136/jcp.2006.038331

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  30 in total

1.  Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies.

Authors:  R A Katzenellenbogen; S B Baylin; J G Herman
Journal:  Blood       Date:  1999-06-15       Impact factor: 22.113

Review 2.  Intrinsic tumour suppression.

Authors:  Scott W Lowe; Enrique Cepero; Gerard Evan
Journal:  Nature       Date:  2004-11-18       Impact factor: 49.962

3.  Infrequent epigenetic dysregulation of CIP/KIP family of cyclin-dependent kinase inhibitors in multiple myeloma.

Authors:  C S Chim; R Liang; T K Fung; Y L Kwong
Journal:  Leukemia       Date:  2005-12       Impact factor: 11.528

4.  Aberrant gene methylation implicated in the progression of monoclonal gammopathy of undetermined significance to multiple myeloma.

Authors:  Chor-Sang Chim; Raymond Liang; Man-Hin Leung; Yok-Lam Kwong
Journal:  J Clin Pathol       Date:  2007-01       Impact factor: 3.411

5.  Expression of p16INK4A and p14ARF in hematological malignancies.

Authors:  T Taniguchi; N Chikatsu; S Takahashi; A Fujita; K Uchimaru; S Asano; T Fujita; T Motokura
Journal:  Leukemia       Date:  1999-11       Impact factor: 11.528

6.  P53 deletion is not a frequent event in multiple myeloma.

Authors:  H Avet-Loiseau; J Y Li; C Godon; N Morineau; A Daviet; J L Harousseau; T Facon; R Bataille
Journal:  Br J Haematol       Date:  1999-09       Impact factor: 6.998

Review 7.  TP53 in hematological cancer: low incidence of mutations with significant clinical relevance.

Authors:  Shoshana Peller; Varda Rotter
Journal:  Hum Mutat       Date:  2003-03       Impact factor: 4.878

8.  SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway.

Authors:  Chor-Sang Chim; Tsz-Kin Fung; Wai-Chung Cheung; Raymond Liang; Yok-Lam Kwong
Journal:  Blood       Date:  2004-02-19       Impact factor: 22.113

Review 9.  Advances in biology of multiple myeloma: clinical applications.

Authors:  Teru Hideshima; P Leif Bergsagel; W Michael Kuehl; Kenneth C Anderson
Journal:  Blood       Date:  2004-04-15       Impact factor: 22.113

Review 10.  Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells.

Authors:  H G Drexler
Journal:  Leukemia       Date:  1998-06       Impact factor: 11.528

View more
  9 in total

1.  Methylation of miR124a-1, miR124a-2, and miR124a-3 in Hodgkin lymphoma.

Authors:  M Ben Dhiab; S Ziadi; F Ksiaa; T Louhichi; R Ben Gacem; A Ben Zineb; K Amara; M Hachana; Mounir Trimeche
Journal:  Tumour Biol       Date:  2014-11-15

2.  Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity.

Authors:  Amir A Toor; Kyle K Payne; Harold M Chung; Roy T Sabo; Allison F Hazlett; Maciej Kmieciak; Kimberly Sanford; David C Williams; William B Clark; Catherine H Roberts; John M McCarty; Masoud H Manjili
Journal:  Br J Haematol       Date:  2012-07-23       Impact factor: 6.998

3.  Epigenetic inactivation of the miR-124-1 in haematological malignancies.

Authors:  Kwan Yeung Wong; Chi Chiu So; Florence Loong; Lap Ping Chung; William Wai Lung Lam; Raymond Liang; George Kam Hop Li; Dong-Yan Jin; Chor Sang Chim
Journal:  PLoS One       Date:  2011-04-22       Impact factor: 3.240

4.  Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients.

Authors:  Chor Sang Chim
Journal:  J Transl Med       Date:  2010-11-26       Impact factor: 5.531

5.  Epigenetic inactivation of the hsa-miR-203 in haematological malignancies.

Authors:  Chor Sang Chim; Kwan Yeung Wong; Chung Ying Leung; Lap Ping Chung; Pak Kwan Hui; Sau Yan Chan; Li Yu
Journal:  J Cell Mol Med       Date:  2011-12       Impact factor: 5.310

Review 6.  Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?

Authors:  Catharina Muylaert; Lien Ann Van Hemelrijck; Anke Maes; Kim De Veirman; Eline Menu; Karin Vanderkerken; Elke De Bruyne
Journal:  Front Oncol       Date:  2022-08-18       Impact factor: 5.738

7.  mRNA expression and hypermethylation of tumor suppressor genes apoptosis protease activating factor-1 and death-associated protein kinase in oral squamous cell carcinoma.

Authors:  Chunyan Li; Lin Wang; Jing Su; Ruhui Zhang; Li Fu; Yanmin Zhou
Journal:  Oncol Lett       Date:  2013-05-17       Impact factor: 2.967

8.  Epigenetic inactivation of mir-34b/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia.

Authors:  Lu Qian Wang; Yok Lam Kwong; Kit Fai Wong; Chi Shan Bonnie Kho; Dong Yan Jin; Eric Tse; Anders Rosèn; Chor Sang Chim
Journal:  J Transl Med       Date:  2014-02-22       Impact factor: 5.531

9.  Knockdown of DNA methyltransferase-1 inhibits proliferation and derepresses tumor suppressor genes in myeloma cells.

Authors:  Wenwen Zhou; Huying Chen; Xiuli Hong; Xiaoqing Niu; Quanyi Lu
Journal:  Oncol Lett       Date:  2014-08-26       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.